delicious
Digg
Facebook
LinkedIn
Mixx
Twitter
Yahoo! Buzz
ArQule to Report Fiscal 2009 Financial Results on March 2, 2010
WOBURN, Mass., Feb 23, 2010 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the fiscal 2009 year-end and fourth quarter on Tuesday, March 2, 2010 at 7:00 a.m. eastern time. The Company will hold a conference call at 9:00 a.m. Eastern Time that day to discuss these results.
|
Conference Call and Webcast |
||
| Date: | Tuesday, March 2, 2010 | |
| Time: | 9:00 a.m., Eastern Time | |
|
Conference Call Numbers |
||
| Domestic (toll free): | (877) 868-1831 | |
| International: | (914) 495-8595 | |
| Webcast: | ||
A replay of the conference call will be available beginning at Noon on March 2 for seven days and can be accessed by dialing toll-free (800) 642-1687 and outside the U.S. (706) 645-9291. The confirmation code for replayed calls is 57465288.
About ArQule
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule's lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company is also conducting Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Company's pre-clinical pipeline includes programs directed toward inhibition of the B-RAF kinase and inhibition of fibroblast growth factor receptor. ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP(TM)), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.
SOURCE: ArQule, Inc.
ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com
Copyright Business Wire 2010